Oncogenic Nucleosomes (oncoNucs)

Mutations in histone proteins occur in diverse cancer types but have been challenging to study in a physiological context. A recent large-scale study of more than 180 tumor types suggests that somatic histone mutations occur in 4% of cancers, highlighting novel epigenetic diversity that may be leveraged for future drug and biomarker development. EpiCypher’s Oncogenic Nucleosomes, or oncoNucs, are assembled using histones with cancer-associated mutations, providing highly relevant nucleosome substrates for cancer research.

Shop oncoNucs

Advancing cancer research with oncoNucs

Study effects of mutations on enzyme activity and chromatin reader binding
Use as substrates for drug / inhibitor testing and HTS
Physiological controls for characterizing chromatin interactions

Learn more:

Recombinant Nucleosomes Brochure
We offer panels of oncoNucs as DNA-barcoded spike-in controls for ChIP-seq. Shop the OncoStat SNAP-ChIP^® Panel
OncoNucs are included in our dCypher™ Nucleosome Panels for comprehensive screening against diverse dNuc substrates.